Research and Markets: Atacicept (Systemic Lupus Erythematosus and Lupus Nephritis) - Forecast and Market Analysis to 2022

DUBLIN--()--Research and Markets (http://www.researchandmarkets.com/research/hm3n34/atacicept) has announced the addition of the "Atacicept (Systemic Lupus Erythematosus and Lupus Nephritis) - Forecast and Market Analysis to 2022" report to their offering.

Systemic lupus erythematosus (SLE) is a systemic inflammatory autoimmune disease that can affect any organ or tissue and is the prototypic autoimmune disease. While SLE can affect multiple major organ systems in the body, one of its most severe manifestations includes renal (kidney) involvement, known as lupus nephritis (LN).

The term LN refers to SLE patients with glomerulonephritis, and when the term LN is used, glomerular tissue injury in the kidneys is always involved. Renal injury without any glomerular involvement is classified as nephritis in a patient with SLE.

Merck Serono is developing atacicept, under license from ZymoGenetics (now Bristol-Myers Squibb), for the potential treatment of autoimmune diseases, including SLE. Atacicept is a fusion protein of the extracellular portion of the transmembrane activator and CAML interactor (TACI) receptor and the Fc portion of human immunoglobulin G (IgG) and is being developed as a subcutaneous formulation.

Scope

- Overview of SLE-LN, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.

- Detailed information on Atacicept including product description, safety and efficacy profiles as well as a SWOT analysis.

- Sales forecast for Atacicept for the top seven countries from 2012 to 2022.

- Sales information covered for the US, France, Germany, Italy, Spain, the UK and Japan

Key Topics Covered:

List of Tables

List of Figures

Introduction

Disease Overview

Disease Management

Competitive Assessment

Opportunity and Unmet Need

Pipeline Assessment

Atacicept

Appendix

For more information visit http://www.researchandmarkets.com/research/hm3n34/atacicept

About Research and Markets

Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Contacts

Research and Markets
Laura Wood, Senior Manager.
press@researchandmarkets.com
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Immune Disorders

Contacts

Research and Markets
Laura Wood, Senior Manager.
press@researchandmarkets.com
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Immune Disorders